A Look Ahead: The results of DESTINY-Breast05 and COMPASS-HER2 RD are set to reshape the HER2+ adjuvant space. Drs. Mouabbi and Kang preview how these potentially practice-changing studies can redefine adjuvant care in HER2+ disease.
DESTINY-Breast05 & COMPASS-HER2 RD: What’s Next in Adjuvant Therapy
You may also like
Recommended Videos
